Home › NDC Lookup › RxCUI directory › RxCUI 2564003

Odevixibat 1.2 MG Oral Capsule — RxCUI 2564003

RxNorm drug concept · Semantic clinical drug
RxCUI 2564003 Semantic clinical drug · SCD ● Current RxNorm concept 8 FDA products 8 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2564003
Official nameOdevixibat 1.2 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asodevixibat 1200 MCG Oral Capsule; odevixibat (as odevixibat sesquihydrate) 1200 MCG Oral Capsule
FDA products mapped8
Package NDCs mapped8
Reported Medicaid activity (SDUD)61 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Odevixibat: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Bylvay works in the intestine to block the recycling of bile acids — substances produced by the liver — back into the bloodstream. In conditions like PFIC and Alagille syndrome, bi...
  • What exactly does Bylvay do, and why does my child need it?
  • Give Bylvay once every morning with the first meal of the day. Capsules should be swallowed whole — do not crush or chew them. The dose is based on your child's weight, so always f...
  • How and when should we give Bylvay each day?
📖 Read our full Odevixibat guide →

🕸️ Concept Web — How Odevixibat 1.2 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Odevixibat 1.2 MG Oral Capsule RxCUI 2564003

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Odevixibat 2563966
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Bylvay 2563984
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Odevixibat Oral Capsule 2563996
    • Odevixibat Oral Product 2563980
    • Odevixibat Pill 2563995
    • Odevixibat Oral Capsule [Bylvay] 2563999
    • Bylvay Oral Product 2563987
    • Bylvay Pill 2564000
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Odevixibat 1.2 MG SCDC · 2564002
  • Odevixibat Oral Capsule SCDF · 2563996
  • Odevixibat Oral Product SCDG · 2563980
  • Odevixibat Pill SCDG · 2563995

Brand-Name Concepts

  • Odevixibat 1.2 MG Oral Capsule [Bylvay] SBD · 2564005
  • Odevixibat 1.2 MG [Bylvay] SBDC · 2564004
  • Odevixibat Oral Capsule [Bylvay] SBDF · 2563999
  • Bylvay Oral Product SBDG · 2563987
  • Bylvay Pill SBDG · 2564000
  • Bylvay BN · 2563984

📦 FDA Products & Package NDCs

8 products · 8 package NDCs
8 package NDCs map to RxCUI 2564003 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
15054-3301-01 1 BOTTLE in 1 CARTON (15054-3301-1) / 30 CAPSULE, COATED PE... Bylvay Ipsen Biopharmaceuticals, Inc. 2024-01-10
15054-3302-01 1 BOTTLE in 1 CARTON (15054-3302-1) / 30 CAPSULE in 1 BOTTL... Bylvay Ipsen Biopharmaceuticals, Inc. 2024-01-10
15054-3303-01 1 BOTTLE in 1 CARTON (15054-3303-1) / 30 CAPSULE, COATED PE... Bylvay Ipsen Biopharmaceuticals, Inc. 2024-01-10
15054-3304-01 1 BOTTLE in 1 CARTON (15054-3304-1) / 30 CAPSULE in 1 BOTTL... Bylvay Ipsen Biopharmaceuticals, Inc. 2024-01-10
74528-0020-01 1 BOTTLE in 1 CARTON (74528-020-01) / 30 CAPSULE, COATED PE... BYLVAY Albireo Pharma, Inc. 2021-07-20
74528-0040-01 1 BOTTLE in 1 CARTON (74528-040-01) / 30 CAPSULE, COATED PE... BYLVAY Albireo Pharma, Inc. 2021-07-20
74528-0060-01 1 BOTTLE in 1 CARTON (74528-060-01) / 30 CAPSULE, COATED PE... BYLVAY Albireo Pharma, Inc. 2021-07-20
74528-0120-01 1 BOTTLE in 1 CARTON (74528-120-01) / 30 CAPSULE, COATED PE... BYLVAY Albireo Pharma, Inc. 2021-07-20
Observed labelers: Albireo Pharma, Inc. (4) · Ipsen Biopharmaceuticals, Inc. (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.